Atty. Dkt. No. 018733-1066

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Milton D. GOLDENBERG

Title:

METHOD AND KIT FOR IMAGING AND TREATING ORGANS AND

TISSUES

Appl. No.:

Unassigned

Filing Date:

12/05/2001

Examiner:

Unassigned

BEST AVAILABLE COPY

Art Unit:

Unassigned

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.56

Commissioner for Patents Box PATENT APPLICATION Washington, D.C. 20231

Sir:

Applicant submits herewith on Form PTO-1449 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 09/110,181, filed July 6, 1998. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.



#2



The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

RELEVANCE OF EACH DOCUMENT

Applicant respectfully requests that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741. BEST AVAILABLE COPY

Respectfully submitted,

Stephen B. Maebius

Attorney for Applicant Registration No. 35,264

Date: December 5, 2001

FOLEY & LARDNER

Customer Number: 22428

22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5569

Facsimile: (202) 672-5399

Page 1 of 2 ATTY, DOCKET NO. SERIAL NO. 018733-1066 Unassigned

U.S. DEPARTMENT OF COMMERCE Form PTO-1449 (MODIFIED) PATENT AND TRADEMARK OFFICE APPLICANT Milton D. GOLDENBERG INFORMATION DISCLOSURE CITATION FILING DATE **GROUP ART UNIT** (Use several sheets if necessary) 12/05/2001 Unassigned **U.S. PATENT DOCUMENTS FILING DATE** DOCUMENT **EXAMINER** SUB-DATE NAME **CLASS REF** IF INITIAL **CLASS** NUMBER **APPROPRIATE** Α1 4,859,449 8/1989 **MATTES** 424 9 4,735,210 4/1988 **GOLDENBERG** 128 654 Α2 547 3/1988 **TOLMAN** 436 А3 4,732,864 424 4,444,744 4/1984 **GOLDENBERG** 1 A4 4,348,376 9/1982 **GOLDENBERG** 424 1 **A5** 1 7/1977 424 4,036,945 **HABER A6 FOREIGN PATENT DOCUMENTS** TRANSLATION DOCUMENT SUB-DATE COUNTRY **CLASS** REF **CLASS NUMBER** YES NO 0 330 201 8/1989 **EUROPE A7** OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) BALDWIN et al., "Monoclonal Antibodies in Cancer Treatment," Lancet Vol. 1:8481, pp. 603-605 (1986). **8**A RESKE et al., "Radioimmunoimaging for Diagnosis of Bone Marrow Involvement in Breast Cancer and Α9 Malignant Lymphoma,"Lancet, Vol. 1, No. 8633, pp. 299-301 (1989). DUNCKER et al., "Radioammune Imaging of Bone Marrow in Patients with Suspected Bone Metastases From A10 Primary Breast Cancer," J. of Nuclear Medicine, Vol. 31, No. 9, pp. 1450-1455 (1990). RESKE et al., Nachweis des Knochenmarkbefalls beim Mammakarzinom und bei malignen Lymphomen durch Immunszintigraphie des hämatopoetischen Knochenmarks," Rofo Fortschr. Geb. Rontgenstr. Neuen A11 Bildgebenden Verfahren Vol. 152, No. 1, pp. 60-66 (1990). SHARKEY et al., "Murine Monoclonal Antibodies Against Carcinoembryonic Antigen" Immunological, Pharmacokinetic, and Targeting Properties in Humans," Cancer Research, Vol. 50, No. 9, pp. 2823-2831 A12 (1990). DELAND et al., "Axiliary Lymphoscintigraphy by Radioimmunodetection of Carcinoembryonic Antigen in Breast A13 Cancer," J. of Nuclear Medicine, Vol. 20, No. 12, pp. 1243-1250 (1979). SIMPSON et al., "The Use of Monoclonal Antibody B72.3 in the Management of Gynecologic Malignancies," A14 Yale Journal of Biological Medicine, Vol. 61, No. 4, pp. 351-366 (1988). **DATE CONSIDERED EXAMINER** EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw

line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Page 2 of 2 Form PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO. SERIAL NO. (MODIFIED) PATENT AND TRADEMARK OFFICE 018733-1066 Unassigned APPLICANT INFORMATION DISCLOSURE CITATION Milton D. GOLDENBERG FILING DATE **GROUP ART UNIT** 12/05/2001 Unassigned (Use several sheets if necessary) **U.S. PATENT DOCUMENTS FILING DATE** DOCUMENT SUB-**EXAMINER** NAME CLASS DATE REF INITIAL **CLASS** NUMBER **APPROPRIATE** FOREIGN PATENT DOCUMENTS TRANSLATION DOCUMENT SUB-DATE COUNTRY **CLASS REF** NUMBER **CLASS** YES NO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) COLCHER et al., "Complementation of Intracavitary and Intravenous Administration of a Monoclonal Antibody A15 (B72.3) in Patients with Carcinoma," Cancer Research, Vol. 47, No. 15, pp 4218-4224 (1987)/ **DATE CONSIDERED EXAMINER** EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.